Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to Partners Including Fujirebio and University Hospital Heidelberg
TOKYO, April 23, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and R&D Projects for NTDs With Partners Including Drugs & Diagnostics for Tropical Diseases and Medical & Biological Laboratories
TOKYO, March 18, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…